$2.42
0.0351.46%
Last update: Nov 11, 4:07 PM
bioAffinity Technologies Inc
BIAFNASDAQ
bioAffinity Technologies fell 92.6% from $32.40 to $2.39, behind the S&P 500's +9.8%. Its worst day was Sep 8 (−41.5%), and its low came Nov 9 at $2.26.
Nov 11, 2025 – Nov 10, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-71.10 missed the $-40.50 estimate on $1.4M revenue (est. $1.4M).
−2.1% · S&P 500 0.0%
EPS of $-16.65 beat the $-40.50 estimate on $1.6M revenue (est. $1.4M).
Story events cover the past 12 months · Times ET
+98.1%, the year's best day · S&P 500 −0.6%
bioAffinity Technologies closed at its highest level of the year, 119.4% above where the year started.
+19.4% · S&P 500 −1.8%
EPS of $-12.15 beat the $-36.00 estimate on $1.4M revenue (est. $1.5M).
−4.2% · S&P 500 +0.8%
EPS of $-9.60 was reported on $1.5M revenue.
−3.7% · S&P 500 +0.6%
bioAffinity Technologies is surging Wednesday as traders digest recent commercial expansion news alongside tight low-float trading dynamics.
+48.0% · S&P 500 +0.4%
Dual patent protection in Hong Kong and China strengthens CyPath Lung’s positioning to enter Asian marketAsia accounts for nearly two-thirds of lung cancer cases worldwidebioAffinity Technologies, Inc.
+63.6% · S&P 500 +0.9%
EPS of $-5.89 was reported on $1.1M revenue.
−16.8% · S&P 500 +2.4%
Where it ended: a close of $2.39 on Nov 10, 2026.
Nothing in the past 12 months.
All BIAF analyst actionsNothing in the past 12 months.
All BIAF dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for BIAF and SPY from Benzinga historical bars. Not investment advice.
